The short version of peptide agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-25 and is reviewed periodically as new material appears.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
== Diagnosis == There are various tools that can be used to help diagnose myositis. The most common methods are physical examination, electromyography (EMG), magnetic resonance imaging (MRI), muscle biopsy, and blood tests. The first course of action a doctor will likely take is perform a physical exam. The doctor assesses for muscle weakness or rashes. Another possible test is electromyography. This test involves the insertion of small needles into the patient's muscles. This allows a physician to look at the muscles' responses to various electrical nerve stimuli and evaluate which muscles potentially have myositis. Magnetic resonance imaging can be useful in diagnosis, allowing painless, non-invasive visualisation of any muscle wastage. Muscle biopsies, however, are the most reliable tests for diagnosing myositis. There are also a variety of blood tests available that help in the diagnosis of myositis. The doctor may look for an elevation of creatine kinase in the blood, which is indicative of muscle inflammation. Certain autoantibodies (antibodies that target muscle cells) can also be found in the blood, which can indicate that myositis is caused by an autoimmune disease. Some specific examples of autoantibodies are Anti-Jo-1, Anti-HMGCR, Anti-TIF1, etc.
Entourage Guimard: Square-Victoria–OACI station on the Montreal Metro in Canada has a genuine Guimard entrance made from parts of demolished Paris entrances (with map holder and "Métropolitain" sign and holder reproduced from the original molds). It was installed in 1967. During restoration in 2001–2002, it was found to have the last examples of the original glass light globes, which in Paris had been replaced with plastic for safety; one was returned to the RATP and the other placed on display in the Montreal Museum of Fine Arts. Bellas Artes station on the Mexico City Metro in Mexico has a Guimard entrance installed in 1998. Picoas station on the Lisbon Metro in Portugal has a Guimard entrance installed in 1995. Kievskaya station on the Moscow Metro in Russia has a Guimard entrance installed in 2007. Van Buren Street station on the Metra Electric District in Chicago had a Guimard entrance installed in 2001. An Entrance to the Paris Métropolitain: The National Gallery of Art in Washington, D.C., United States has a Guimard entrance in its sculpture garden, first shown at the gallery in a 2000–2001 exhibition on Art Nouveau and permanently installed in the garden in 2003. The Museum of Modern Art in New York City, United States has the archway consisting of the light stalks and "Métropolitain" sign from the Guimard entrance to Raspail station. The Dali Theater Museum in Figueres (Girona, Spain) has a pair of the light stalks from a Guimard Métro entrance, which are exhibited on the patio.
=== Zwitterion === Zwitterions contain an anionic and a cationic centre in the same molecule, but are not considered salts. Examples of zwitterions are amino acids, many metabolites, peptides, and proteins.
=== Audio and video === Audio of Ian Smith's radio address announcing UDI 2 years of independence, 1967 Rhodesian MoI film (7 mins) on YouTube Rhodesia to Zimbabwe, collection of film clips (6 mins) on YouTube Songs of UDI, 3 songs from 1977 (9 mins) on YouTube
Sources: en.wikipedia.org
== Causes == Leptomeningeal carcinomatosis occurs when the cancer cells invade the cerebrospinal fluid and spread throughout the central nervous system. The metastatic tumor cells grow either attached to the pia mater covering the brain and spinal cord or floating unattached to the subarachnoid space. Tumors of diverse origins and hematologic cancers may spread to this space. Some patients may develop leptomeningeal cancer while receiving chemotherapy for their primary tumour, partly because the blood-brain barrier serves as a protective filter that shields the central nervous system from toxins and pathogens circulating in the blood. While essential for protection, this barrier also complicates treatment, as many chemotherapy agents and biopharmaceuticals struggle to cross into the brain and spinal cord.
=== Systemic involvement === Malaise and low-grade fever may develop with MCTD. The condition can cause elevated body temperatures without a clear cause. Sicca symptoms are frequent in MCTD, affecting 25-50% of individuals.
== In leukocytes == A group of leukocytes, called granulocytes, are white blood cells containing enzyme granules that play a significant role in the immune system. Granulocytes include neutrophils, eosinophils, and basophils which attack bacteria or parasites, and respond to allergens. Each type of granulocyte contains enzymes and chemicals tailored to its function. Neutrophils for example, contain primary granules, secondary granules, tertiary granules, and secretory vesicles. Primary vesicles, also known as azurophilic granules, secrete hydrolytic enzymes including elastase, myeloperoxidase, cathepsins, and defensins that aid in pathogen destruction. Secondary granules, or specific granules, in neutrophils contain iron-binding protein lactoferrin. Tertiary granules contain matrix metalloproteinases. Other immune cells, such as natural killer cells, contain granular enzymes, including perforin and proteases which can lead to the lysis of neighboring cells. The process by which granule contents are released is known as degranulation. This tightly controlled process is initiated by immunological stimuli and results in the movement of granules to the cell membrane for fusion and release.
=== Liberal Leaders in the House of Commons === Henry John Temple, 3rd Viscount Palmerston (1859–1865) William Ewart Gladstone (1865–1875) Spencer Cavendish, 8th Duke of Devonshire (1875–1880) William Gladstone (1880–1894) Sir William Harcourt (1894–1898) Henry Campbell-Bannerman (1899–1908) H. H. Asquith (1908–1916)
== History == Some of the most important discoveries relating to transferases occurred as early as the 1930s. Earliest discoveries of transferase activity occurred in other classifications of enzymes, including beta-galactosidase, protease, and acid/base phosphatase. Prior to the realization that individual enzymes were capable of such a task, it was believed that two or more enzymes enacted functional group transfers.
Sources: en.wikipedia.org
=== β-α-β motif === Due to the chirality of their component amino acids, all strands exhibit right-handed twist evident in most higher-order β-sheet structures. In particular, the linking loop between two parallel strands almost always has a right-handed crossover chirality, which is strongly favored by the inherent twist of the sheet. This linking loop frequently contains a helical region, in which case it is called a β-α-β motif. A closely related motif called a β-α-β-α motif forms the basic component of the most commonly observed protein tertiary structure, the TIM barrel.
==== Firearms and criminal justice ==== In 1993, Sanders voted against the Brady Bill, which mandated federal background checks when buying guns and imposed a waiting period on firearm purchasers in the United States; the bill passed by a vote of 238–187. He voted against the bill four more times in the 1990s, explaining that his Vermont constituents saw waiting-period mandates as more appropriately a state rather than a federal matter. Sanders did vote for other gun-control measures. For example, in 1994, he voted for the Violent Crime Control and Law Enforcement Act "because it included the Violence Against Women Act and the ban on certain assault weapons." He was nevertheless critical of the other parts of the bill. Although he acknowledged that "clearly, there are some people in our society who are horribly violent, who are deeply sick and sociopathic, and clearly these people must be put behind bars in order to protect society from them", he maintained that governmental policies played a large part in "dooming tens of millions of young people to a future of bitterness, misery, hopelessness, drugs, crime, and violence" and argued that the repressive policies introduced by the bill were not addressing the causes of violence, saying, "we can create meaningful jobs, rebuilding our society, or we can build more jails." Sanders has at times favored stronger law enforcement and sentencing. In 1996, he voted against a bill that would have prohibited police from purchasing tanks and armored carriers.
=== Absorption and transport === Inadequate absorption of vitamin B12 may be related to coeliac disease. Intestinal absorption of vitamin B12 requires successively three different protein molecules: haptocorrin, intrinsic factor and transcobalamin II.
Rendered unable to throw from his surgery, Bagwell was activated in September as a pinch hitter, and he played a symbolic role in the successful drive to capture their first-ever National League pennant and World Series appearance. Moreover, the Astros secured the pennant against their division rival St. Louis Cardinals in the NLCS, reversing the outcome from the year prior against the same club. After having played 4,714 games and their entire major league careers together in Houston, Bagwell and Biggio appeared in their first World Series in 2005. Bagwell was the Astros' designated hitter in the first two games against the White Sox at U.S. Cellular Field, and was a pinch hitter in the two games played in Houston at Minute Maid Park. His last official major league plate appearance was in the seventh inning of Game 4, when he pinch-hit for pitcher Brandon Backe and grounded out. The White Sox won this contest to sweep the Astros and secure the championship. The White Sox outscored the Astros by a combined six runs, the lowest scoring differential in World Series history. Together with Biggio, and longtime Astros executive Tal Smith, Bagwell received Baseball America's Lifetime Achievement Award after the 2005 season.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.